Ken received his Ph.D. from the University of Utah in 1996 and came to Eli Lilly and Co. in 1998 from the Memorial Sloan Kettering Cancer Research Center as a senior organic chemist. He worked on several projects as a medicinal chemist in the areas of anxiety, depression and inflammatory disorders, and he has been involved in many cross-functional Lilly research collaborations.
In the fall of 2004, Ken went into the Lean / 6-Sigma program at Lilly and led ten projects as a 6-Sigma Black Belt before moving back to chemistry as the Head of Global Operations for Discovery Chemistry Research and Technology.
In 2008, Ken took on new a new role as a Head in Drug Disposition with responsibilities across the in-vitro, transporter, in-silico, Lead Generation and the isotopic chemistry groups within Drug Disposition.
In 2009, Ken moved to Global External R&D (GER&D) where he worked to better define the approach to sourcing and pre-diligence assessment of pre-clinical / discovery level opportunities.
Ken moved into the role of Director of process chemistry and route design in early 2012 and then to the role of Technology, Design and Development Advisor for the Lilly development organization and then to the Clinical Innovation Group at Lilly. Ken has championed new knowledge management and innovation initiatives.
In May 2017 Ken retired from Lilly and is currently working with Xylogenics (a small biotech located in Indianapolis) while also working in the Commercial Innovation team and the Science and Technology teams at CASIS (Center for the Advancement of Science in Space).